Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 1
1999 5
2000 4
2001 3
2002 1
2003 6
2004 5
2005 10
2006 3
2007 3
2008 1
2009 3
2010 4
2011 2
2012 2
2013 4
2016 2
2017 2
2018 2
2019 1
2020 1
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 15347709

66 results

Results by year

Filters applied: . Clear all
Page 1
High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis-I). A phase I, open-label, two-year follow-up trial.
Favaloro L, Diez M, Mendiz O, Janavel GV, Valdivieso L, Ratto R, Garelli G, Salmo F, Criscuolo M, Bercovich A, Crottogini A. Favaloro L, et al. Catheter Cardiovasc Interv. 2013 Nov 15;82(6):899-906. doi: 10.1002/ccd.24555. Epub 2013 Jun 5. Catheter Cardiovasc Interv. 2013. PMID: 22777825 Clinical Trial.
Comparative evaluation of long-term clinical efficacy with catheter-based percutaneous intramyocardial autologous bone marrow cell implantation versus laser myocardial revascularization in patients with severe coronary artery disease.
Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Bastian B, Chan JK, Lo G, Ho CL, Parker A, Hauser TH, Lau CP. Tse HF, et al. Am Heart J. 2007 Nov;154(5):982.e1-6. doi: 10.1016/j.ahj.2007.07.021. Epub 2007 Sep 6. Am Heart J. 2007. PMID: 17967607
Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD).
Kukuła K, Chojnowska L, Dąbrowski M, Witkowski A, Chmielak Z, Skwarek M, Kądziela J, Teresińska A, Małecki M, Janik P, Lewandowski Z, Kłopotowski M, Wnuk J, Rużyłło W. Kukuła K, et al. Am Heart J. 2011 Mar;161(3):581-9. doi: 10.1016/j.ahj.2010.11.023. Epub 2011 Jan 31. Am Heart J. 2011. PMID: 21392615 Clinical Trial.
Evaluation of myocardial perfusion and left ventricular function six months after percutaneous transmyocardial laser revascularization: comparison of two Ho-YAG laser systems with the same wavelength, but different energy delivery and navigation systems.
Strehblow C, Gyöngyösi M, Khorsand A, Sperker W, Gatterer M, Graf S, Sochor H, Glogar D. Strehblow C, et al. Lasers Surg Med. 2003;33(5):273-81. doi: 10.1002/lsm.10230. Lasers Surg Med. 2003. PMID: 14677154
Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment.
Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL, Charbonneau F, Cohen E, Curtis M, Buller CE, Mendelsohn FO, Dib N, Page P, Ducas J, Plante S, Sullivan J, Macko J, Rasmussen C, Kessler PD, Rasmussen HS. Stewart DJ, et al. Gene Ther. 2006 Nov;13(21):1503-11. doi: 10.1038/sj.gt.3302802. Epub 2006 Jun 22. Gene Ther. 2006. PMID: 16791287 Clinical Trial.
66 results